GNPX

New Clinical Trial Site: Genprex, Inc. has added Gabrail Cancer Center in Canton, Ohio, as a new site for its Acclaim-1 and Acclaim-3 clinical trials, aimed at expanding patient access to its Reqorsa® Gene Therapy for lung cancer.

FDA Fast Track Designation: Both Acclaim-1 and Acclaim-3 trials have received FDA Fast Track Designation, which is intended to expedite the development and review of therapies that address unmet medical needs.

Acclaim-1 Trial Details: The Acclaim-1 trial is a Phase 1/2 study evaluating Reqorsa in combination with AstraZeneca's Tagrisso for late-stage non-small cell lung cancer, with early results showing promising efficacy and tolerability.

Acclaim-3 Trial Details: The Acclaim-3 trial is a Phase 1/2 study assessing Reqorsa alongside Genentech's Tecentriq as maintenance therapy for extensive stage small cell lung cancer, with plans for interim analysis after enrolling 25 patients.

Funding Announcement: Genprex, Inc. has entered into agreements to issue 377,780 shares of common stock at $9.00 per share, aiming for gross proceeds of approximately $3.4 million, with potential additional proceeds of $6.6 million from short-term warrants.

Use of Proceeds: The company plans to utilize the net proceeds from this offering for working capital and general corporate purposes, with the closing expected around October 29, 2025, pending customary conditions.

Company Overview: Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes to patients with limited treatment options.

Regulatory Compliance: The shares are being offered under a "shelf" registration statement, while the unregistered warrants are offered in a private placement, adhering to the Securities Act regulations.